Cisplatin-Associated Acute Kidney Injury (CP-AKI) Risk Calculator
ورودیهای بالینی بیمار
حداقل ۱۸ — حداکثر ۱۱۰ • واحد: years
حداقل ۱ — حداکثر ۱۰۰۰ • واحد: mg
حداقل ۲ — حداکثر ۲۰ • واحد: g/dL
حداقل ۱ — حداکثر ۳۰۰ • واحد: ×10³/µL
حداقل ۱ — حداکثر ۱۵۰۰ • واحد: ×10³/µL
حداقل ۰.۵ — حداکثر ۸ • واحد: g/dL
حداقل ۰.۵ — حداکثر ۵ • واحد: mg/dL
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- —0–5
- —5–15
- —15–30
- —30–100
The Cisplatin-Associated Acute Kidney Injury (CP-AKI) Risk Calculator calculates predicting the risk of acute kidney injury in patients treated with intravenous cisplatin. Key inputs include age. Scores guide adjusting renal medication clearance, coordinating nephrology follow-up, or planning renal replacement therapy. Routine clinical application promotes standardized evidence-based patient management.
Clinical Guidelines & Evidence
Predicts the risk of acute kidney injury in patients treated with intravenous cisplatin. This calculator estimates the probability of moderate to severe AKI (≥2-fold rise in serum creatinine or need for kidney replacement therapy within 14 days of cisplatin administration).
Clinical Indication
The Cisplatin-Associated Acute Kidney Injury (CP-AKI) Risk Calculator is indicated for bedside clinical practice to support Predicts the risk of acute kidney injury in patients treated with intravenous cisplatin. This calculator estimates the probability of moderate to severe AKI (≥2-fold rise in serum creatinine or need for kidney replacement therapy within 14 days of cisplatin administration).. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with acute kidney injury (AKI), chronic kidney disease stages 1-5, or acid-base and fluid-electrolyte disturbances. Clinical application is indicated across Nephrology clinics, hemodialysis units, acute inpatient renal services, and metabolic wards.
Limitations & Contraindications
eGFR estimation equations assume steady-state serum creatinine and become unreliable during unstable AKI, amputations, or extremes of muscle mass.
Clinical Pearls & Action Plan
Serum creatinine lags behind acute reductions in glomerular filtration; monitor hourly urine output and consider cystatin C in evolving AKI.
Risk (%) = 1 / (1 + e^(-X)) × 100, where X is calculated using patient characteristics including age, comorbidities, and laboratory values
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| age | integer | Yes | Patient age in years(years) |
| hypertension | string | Yes | History of hypertension |
| diabetes | string | Yes | History of type 2 diabetes mellitus |
| cisplatin_dose | float | Yes | Total cisplatin dose(mg) |
| hemoglobin | float | Yes | Hemoglobin level(g/dL) |
| wbc_count | float | Yes | White blood cell count(×10³/µL) |
| platelet_count | float | Yes | Platelet count(×10³/µL) |
| albumin | float | Yes | Serum albumin level(g/dL) |
| magnesium | float | Yes | Serum magnesium level(mg/dL) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–5 | — | Low risk |
| 5–15 | — | Moderate risk |
| 15–30 | — | High risk |
| 30–100 | — | Very high risk |
Evidence-Based References (EBM)
- Gupta S, Portales-Castillo I, Daher A, Kitchlu A. Derivation and external validation of a simple risk score for predicting severe acute kidney injury after intravenous cisplatin: cohort study. BMJ. 2024 Mar 27;384:e077169. doi: 10.1136/bmj-2023-077169.DOI: 10.1136/bmj-2023-077169
- Motwani SS, McMahon GM, Humphreys BD, Partridge AH, Waikar SS, Curhan GC. Development and Validation of a Risk Prediction Model for Acute Kidney Injury After the First Course of Cisplatin. J Clin Oncol. 2018 Mar 1;36(7):682-688. doi: 10.1200/JCO.2017.75.7161.DOI: 10.1200/JCO.2017.75.7161